Atrial Fibrillation Trial To Eliminate Risk-factors

Atrial Fibrillation Clinical Trial

— AFTTER  

Official title:

Atrial Fibrillation Trial To Eliminate Risk-factors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05718336
• Other study ID #: 202003090RINA
• Status: Recruiting
• Start date: May 1, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2023
• Source: National Taiwan University Hospital
• Contact: Chih-Chieh Yu, MD.PhD
• Phone: 886-2-23123456
• Email: sweetchieh[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this prospective-enrolling cohort study is to test and observe the effect of an integrated multi-discipline care program in patients with atrial fibrillation. The main questions it aims to answer are:

1. to understand the baseline characteristics and to explore the occult risk factors of the patients with AF;

2. to monitor the treatment efficacy of the patients undergoing integrated care and potentially concur the clinical obstacles that prevent the best care for patients with AF.

Participants will be treated by an integrated multi-discipline team that led by an electro-physiologist.

Description:

Atrial fibrillation (AF) is a heart condition that potentially leads to heart failure and ischemic stroke. The prevalence of AF is increasing due to aging population and improved treatment in other cardiovascular field. This study is to execute integrated multi-discipline care in a tertiary hospital, and to observe the effect and the obstacle that the program might ensue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• At least 20 years old, who have been diagnosed with atrial fibrillation by a cardiologist with an electrocardiogram

Exclusion Criteria:

1. Unable to complete the initial assessment and cooperate with the tracker

2. Those who refuse to sign the subject's consent

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Other:
• Integrated care
multi-discipline care program

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospita	Taipei,

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AF burden	The duration in AF on 14-day ECG monitor (percent)	0~24 months
Secondary	MACE, major adverse cardiovascular event	ischemic heart disease with acute coronary syndrome, stroke (either ischemic or hemorrhagic stroke), cardiovascular death, and all-cause death	0~24 months